Biomay – discovery, research and development of innovative allergy therapeutics.
The privately held company pioneers the diagnostic and therapeutic use of recombinant allergens.”

Message from the CEO

Rainer HenningDear Visitor:

The new year is off to a great start for Biomay. 

The launch of  IgEnio®, the innovative medical device for the treatment of IgE by our partner Fresenius Medical Care is progressing. Additional clinical studies, which will further elucidate the therapeutic potential of the product, are in planning and will begin later this year. We strongly believe that this treatment will bring new hope to patients with severe asthma, atopic dermatitis or other allergic diseases, who currently have very few treatment options.

 This launch is very significant for Biomay, since the product was co-developed with us, and it contains our single-chain antibody fragment (BM10) as ligand. This highly potent antibody was discovered in Vienna in cooperation with Prof. Rudolf Valenta at the Medical University; Biomay holds the patent rights. Our manufacturing team has successfully developed an efficient and scalable manufacturing process for BM10, which will be the basis for commercial production. We have been able to produce the amount of material required for the impending market launch under strict GMP conforming conditions.

We continue to experience a strong demand for our GMP manufacturing services for plasmid DNA. This is in connection with the resurgence of gene therapy, which has made headlines over the last year. We benefit from the fact that we are one of just a handful of manufacturers world-wide with this capability in the lot sizes required for gene therapy approaches. If you are working for a company developing gene therapy products in the clinic, we would love to talk to you!

We have recently initiated another phase IIb clinical study to optimize the dose regimen of our lead allergy vaccine BM32, which will evaluate an optimized dose regimen for this highly innovative product. We expect to obtain results from this trial later this year. These results will set the product up for phase III trials leading to marketing authorization. 

Finally, please visit our allergen web shop, as we have launched some additional products in our line-up of recombinant allergen proteins. A number of further launches are planned in the near future!

Best regards

Rainer Henning
Chief Executive Officer

Latest News

Biomay has been granted U.S. patent for peptide carrier fusion allergy vaccines ( 4 Feb. 2016)

Biomay announced today that the company received a notice of allowance from the United States...

[more]

go to news archive